Physician profile
Todd E Fox
NPI 1700856358
$1,337.40
in general payments reported to CMS, 2019-2025
25 companies · $48.35 in 2025
The $48.35 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $109 · 2020: $132 · 2021: $498 · 2022: $313 · 2023: $113 · 2024: $124 · 2025: $48.35.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $236 · Long Term Medical Supply Or Device Loan: $49.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $236.06 |
| Long Term Medical Supply Or Device Loan | $49.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $301.43 | 2021-2023 | |
| Abbott Laboratories | $173.33 | 2019-2024 | Freestyle Insulinx |
| Pfizer INC. | $109.01 | 2019-2025 | |
| Amgen INC. | $90.09 | 2020-2022 | |
| Biohaven Pharmaceuticals, INC. | $73.54 | 2020-2021 | |
| Novo Nordisk INC | $73.04 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Janssen Pharmaceuticals, INC | $69.76 | 2019-2022 | |
| Lilly USA, LLC | $61.58 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $53.44 | 2021-2022 | |
| Boston Scientific Corporation | $44.44 | 2024 | Watchman Flx |
| Amarin Pharma, INC. | $38.22 | 2019-2021 | |
| Astrazeneca Pharmaceuticals Lp | $27.15 | 2020-2022 | |
| Allergan, INC. | $25.34 | 2020 | |
| Biogen, INC. | $23.62 | 2023 | Skyclarys |
| Astellas Pharma US INC | $22.45 | 2021 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $22.15 | 2021 | |
| Celgene Corporation | $15.84 | 2023 | Reblozyl |
| Dexcom, INC. | $15.14 | 2024 | Dexcom G6 Transmitter |
| Lifescan, INC. | $15.13 | 2023 | |
| Genentech USA, INC. | $14.91 | 2021 | |
| Eisai INC. | $14.71 | 2020 | |
| Aytu Biopharma, INC. | $13.65 | 2019 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $13.55 | 2022 | |
| Glaxosmithkline, LLC. | $13.32 | 2022 | |
| Merck Sharp & Dohme LLC | $12.56 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Todd Fox listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.